Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib, Binimetinib Plus Cetuximab in Previously Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer
NCT03693170Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jan 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of encorafenib, binimetinib, KL-140 in colorectal cancer (CRC), sponsored by Pierre Fabre Laboratories. Started Jan 2019; status: completed.
02
Drugs
encorafenibbinimetinibKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03693170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693170.